Results 51 to 60 of about 6,313 (203)

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension [PDF]

, 2015
Peer ...
Bergenstal, R. M., Bolli, G. B., Maroccia, M., Muehlen-Bartmer, I., Riddle, M. C., Wardecki, M., Yki-Järvinen, H., Ziemen, M.   +7 more
core   +1 more source

Insulin therapy DE‐intensificAtion with iGlarLixi: A phase 4, open‐label, parallel‐group randomised controlled trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate the efficacy and safety of transitioning from multiple daily injections (MDIs) insulin regimen to once‐daily, fixed‐ratio combination of basal insulin analog glargine 100 U/mL and a glucagon‐like peptide 1 receptor agonist lixisenatide (iGlarLixi) in people with type 2 diabetes (PwT2D). Materials and Methods Insulin therapy DE‐
Peter Novodvorský, Lenka Thieme, Ivana Laňková, Štěpánka Franková, Alica Veselá, Emil Záhumenský, Tomáš Edelsberger, Marie Löblová, Ondřej Žižka, Miroslav Vytasil, Felipe Lauand, Mireille Bonnemaire, Filip Hrubý, Miloš Mráz, Martin Haluzík   +14 more
wiley   +1 more source

Long‐acting insulin analogues and the risk of diabetic nephropathy among patients with type 2 diabetes: A population‐based cohort study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The risk of diabetic nephropathy among patients with type 2 diabetes (T2D) can be reduced through optimal glycaemic control. It is not known if the pharmacological properties of long‐acting insulin analogues may reduce the risk of diabetic complications compared with neutral protamine Hagedorn (NPH) insulin.
Julia Brillinger, Christopher Filliter, Shahrzad Salmasi, Estefania Zapata‐Bravo, Robert W. Platt, Oriana H. Y. Yu, Kristian B. Filion   +6 more
wiley   +1 more source

Retrospective trial of long acting analogues detemir and degludec usage in children and adolescents to overcome glucose variability caused by dawn phenomenon and reverse dawn phenomenon

Сахарный диабет, 2021
Backgraund: Children with type 1 diabetes mellitus (T1DM) need more insulin late in the evening (reverse dawn phenomenon (RDP)), and adolescents need more insulin yearly in the morning (dawn phenomenon (DP)); these cause blood glucose variability. Modern
A. V. Vitebskaya, E. V. Shreder, A. V. Popovich, E. A. Pisareva   +3 more
doaj   +1 more source

Atypical blood glucose response to continuous and interval exercise in a person with type 1 diabetes: a case report [PDF]

, 2017
BackgroundTherapy must be adapted for people with type 1 diabetes to avoid exercise-induced hypoglycemia caused by increased exercise-related glucose uptake into muscles. Therefore, to avoid hypoglycemia, the preexercise short-acting insulin dose must be
Alexander Mueller, DJ West, EA Richter, Gerd Koehler, Gerhard Tschakert, JE Pinsker, Max L. Eckstein, MC Riddell, MP Francescato, O Moser, Othmar Moser, P Galassetti, Peter Hofmann, Richard M. Bracken, Thomas R. Pieber, VB Shetty, Werner Groeschl   +16 more
core   +1 more source

Efficacy and safety of switching basal insulin to insulin glargine 300 U/mL in individuals with inadequately controlled type 2 diabetes on advanced insulin therapies: The Toujeo‐Neo T2DM study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This real‐world study evaluated the effectiveness and safety of switching basal insulin (BI) to insulin glargine 300 U/mL (Gla‐300) in adults with inadequately controlled type 2 diabetes mellitus (T2DM), previously receiving basal‐supported oral therapy plus prandial insulin (BOTplus) or multiple (≥3) daily injections (MDI) of short ...
Stefan Pscherer, Andreas Fritsche, Helmut Anderten, Katrin Pegelow, Henry Y. Han, Martin Pfohl, Jochen Seufert   +6 more
wiley   +1 more source

A novel detrimental homozygous mutation in the WFS1 gene in two sisters from nonconsanguineous parents with untreated diabetes insipidus [PDF]

, 2019
Given the limited lifespan and with the recent progress in experimental treatments for WS, timely diagnosis and multidisciplinary treatment for DI/DM, hydronephrosis, and visual/psychiatric status-maintaining quality of life-are of crucial ...
Delides, Alexandros, Dinopoulos, Argyrios, Kleanthous, Kleanthis, Manolakos, Emmanouil, Mastorakos, Georgios, Nikolopoulos, Thomas, Papadimitriou, Anastasios, Papadimitriou, Dimitrios T, Tiulpakov, Anatoly, Urano, Fumihiko, Voros, Gerasimos, Zoupanos, George   +11 more
core   +2 more sources

United States experience of insulin Degludec alone or in combination for type 1 and type 2 diabetes

Drug Design, Development and Therapy, 2017
Marc Rendell1,2 1The Rose Salter Medical Research Foundation, 2The Association of Diabetes Investigators, Newport Coast, CA, USA Abstract: Insulin degludec has been the product of a sophisticated and systematic biochemical engineering program which ...
Rendell M
doaj  

Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates [PDF]

, 2014
Since its discovery and isolation, exogenous insulin has dramatically changed the outlook for patients with diabetes. However, even when patients strictly follow an insulin regimen, serious complications can result as patients experience both ...
Anderson, Daniel Griffith, Chou, Danny Hung-Chieh, Cortinas, Abel Bryan, Deng, David, Langer, Robert S, Lin, Amy B., Tang, Benjamin C., Thapa, Lavanya S., Truong, Jonathan V., Webber, Matthew   +9 more
core   +1 more source

Effects of age and disease duration on the glycaemic outcomes and safety of insulin glargine 300 U/mL in people with type 2 diabetes in China: A post‐hoc analysis of the INITIATION study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate the glycaemic outcomes and safety of insulin glargine 300 U/mL (Gla‐300) in Chinese people with uncontrolled type 2 diabetes (T2D) by baseline age and disease duration. Materials and Methods INITIATION was a 24‐week, interventional, single‐arm study where adults with T2D (glycated haemoglobin [HbA1c] 7.5%–11.0%) received Gla ...
Liming Chen, Qiu Zhang, Binhong Duan, Xiaohong Wu, Hailong Wan, Binhong Wen, Jie Han, Haixia Liu, Caixian Yang, Weiwei Liu, Qin Du, Lei Kang, Minlu Zhang   +12 more
wiley   +1 more source